Enovis (NYSE:ENOV) Trading Down 7.9% – What’s Next?

Enovis Corporation (NYSE:ENOV)’s stock price traded down 7.9% during trading on Tuesday . The company traded as low as $20.11 and last traded at $20.2730. 87,471 shares changed hands during mid-day trading, a decline of 92% from the average session volume of 1,058,294 shares. The stock had previously closed at $22.02.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Wall Street Zen cut Enovis from a “buy” rating to a “hold” rating in a research note on Sunday. Evercore reaffirmed an “outperform” rating and issued a $36.00 price objective on shares of Enovis in a research note on Friday, May 8th. Zacks Research cut Enovis from a “strong-buy” rating to a “hold” rating in a report on Monday, June 1st. William Blair started coverage on Enovis in a research report on Friday, April 17th. They set an “outperform” rating on the stock. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Enovis in a research report on Friday, April 10th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $44.50.

Enovis Stock Down 11.5%

The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.05 and a current ratio of 2.04. The company’s fifty day moving average price is $23.51 and its 200-day moving average price is $24.00. The stock has a market cap of $1.12 billion, a P/E ratio of -0.97 and a beta of 1.38.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.89 EPS for the quarter, beating the consensus estimate of $0.82 by $0.07. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The company had revenue of $589.15 million for the quarter, compared to the consensus estimate of $572.02 million. During the same period in the prior year, the firm posted $0.81 EPS. The firm’s revenue was up 5.4% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Equities analysts forecast that Enovis Corporation will post 3.65 EPS for the current year.

Insider Activity

In other Enovis news, insider Oliver Engert bought 1,200 shares of the business’s stock in a transaction dated Thursday, June 11th. The shares were purchased at an average price of $21.62 per share, with a total value of $25,944.00. Following the completion of the purchase, the insider owned 51,840 shares in the company, valued at $1,120,780.80. This represents a 2.37% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders purchased a total of 4,200 shares of company stock worth $92,084 in the last ninety days. 2.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Enovis

Institutional investors and hedge funds have recently modified their holdings of the business. Arax Advisory Partners bought a new position in Enovis in the 4th quarter valued at $29,000. EverSource Wealth Advisors LLC lifted its position in shares of Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after purchasing an additional 707 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Enovis by 353.5% during the fourth quarter. GAMMA Investing LLC now owns 1,855 shares of the company’s stock valued at $49,000 after purchasing an additional 1,446 shares during the period. Danske Bank A S purchased a new stake in shares of Enovis during the third quarter valued at $64,000. Finally, iSAM Funds UK Ltd bought a new position in shares of Enovis in the third quarter worth about $80,000. 98.45% of the stock is owned by institutional investors.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.